[go: up one dir, main page]

WO2006042034A3 - Salt and crystalline forms thereof of a drug - Google Patents

Salt and crystalline forms thereof of a drug Download PDF

Info

Publication number
WO2006042034A3
WO2006042034A3 PCT/US2005/036024 US2005036024W WO2006042034A3 WO 2006042034 A3 WO2006042034 A3 WO 2006042034A3 US 2005036024 W US2005036024 W US 2005036024W WO 2006042034 A3 WO2006042034 A3 WO 2006042034A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
salt
crystalline forms
inhibition
diseases
Prior art date
Application number
PCT/US2005/036024
Other languages
French (fr)
Other versions
WO2006042034A2 (en
WO2006042034A8 (en
Inventor
Geoff G Zhang
Michael F Bradley
David M Barnes
Rodger Henry
Original Assignee
Abbott Lab
Geoff G Zhang
Michael F Bradley
David M Barnes
Rodger Henry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Geoff G Zhang, Michael F Bradley, David M Barnes, Rodger Henry filed Critical Abbott Lab
Priority to EP21196428.3A priority Critical patent/EP3957632A1/en
Priority to MX2007004111A priority patent/MX2007004111A/en
Priority to EP05825344A priority patent/EP1802607A2/en
Priority to EP15199355.7A priority patent/EP3056492B1/en
Priority to PL15199355T priority patent/PL3056492T3/en
Priority to JP2007535819A priority patent/JP5294633B6/en
Priority to CA2582954A priority patent/CA2582954C/en
Publication of WO2006042034A2 publication Critical patent/WO2006042034A2/en
Publication of WO2006042034A3 publication Critical patent/WO2006042034A3/en
Publication of WO2006042034A8 publication Critical patent/WO2006042034A8/en
Priority to CY20211101121T priority patent/CY1125048T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/18—Polyhydroxylic acyclic alcohols
    • C07C31/26—Hexahydroxylic alcohols

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
PCT/US2005/036024 2004-10-08 2005-10-07 Salt and crystalline forms thereof of a drug WO2006042034A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP21196428.3A EP3957632A1 (en) 2004-10-08 2005-10-07 Meglumine salt and crystalline forms thereof of a drug (delafloxacin)
MX2007004111A MX2007004111A (en) 2004-10-08 2005-10-07 Salt and crystalline forms thereof of a drug.
EP05825344A EP1802607A2 (en) 2004-10-08 2005-10-07 Salt and crystalline forms thereof of a drug
EP15199355.7A EP3056492B1 (en) 2004-10-08 2005-10-07 Meglumine salt and crystalline forms thereof of a drug (delafloxacin)
PL15199355T PL3056492T3 (en) 2004-10-08 2005-10-07 Meglumine salt and crystalline forms thereof of a drug (delafloxacin)
JP2007535819A JP5294633B6 (en) 2004-10-08 2005-10-09 Drug salt and its crystalline form
CA2582954A CA2582954C (en) 2004-10-08 2005-10-09 Salt and crystalline forms thereof of 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylic acid
CY20211101121T CY1125048T1 (en) 2004-10-08 2021-12-21 MEGLUMINE SALT AND CRYSTALLINE FORMS OF THIS DRUG (DELAFLOXACIN)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61733404P 2004-10-08 2004-10-08
US60/617,334 2004-10-08

Publications (3)

Publication Number Publication Date
WO2006042034A2 WO2006042034A2 (en) 2006-04-20
WO2006042034A3 true WO2006042034A3 (en) 2006-06-22
WO2006042034A8 WO2006042034A8 (en) 2007-09-07

Family

ID=36129950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/036024 WO2006042034A2 (en) 2004-10-08 2005-10-07 Salt and crystalline forms thereof of a drug

Country Status (13)

Country Link
US (8) US7728143B2 (en)
EP (3) EP3056492B1 (en)
CA (1) CA2582954C (en)
CY (1) CY1125048T1 (en)
DK (1) DK3056492T3 (en)
ES (1) ES2901955T3 (en)
HU (1) HUE056718T2 (en)
LT (1) LT3056492T (en)
MX (1) MX2007004111A (en)
PL (1) PL3056492T3 (en)
PT (1) PT3056492T (en)
SI (1) SI3056492T1 (en)
WO (1) WO2006042034A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576216B2 (en) 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
EP3056492B1 (en) * 2004-10-08 2021-09-22 AbbVie Inc. Meglumine salt and crystalline forms thereof of a drug (delafloxacin)
WO2006110815A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
DK2346855T3 (en) 2008-09-24 2017-07-24 Melinta Therapeutics Inc PROCEDURE FOR PREPARING QUINOLONE COMPOSITIONS
AU2009314072C1 (en) 2008-11-15 2016-11-10 Melinta Subsidiary Corp. Antimicrobial compositions
MX2015011651A (en) * 2013-03-08 2016-08-08 Melinta Therapeutics Inc Crystalline forms of d-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3, 5-difluoropyridine-2-yl)-8-chloro-6-fluoro-1, 4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxyla te.
KR102237887B1 (en) 2013-03-15 2021-04-07 멜린타 서브시디어리 코프. Methods of treating infections in overweight and obese patients using antibiotics
TWI732337B (en) * 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 Pharmaceutical composition and use thereof
TW201605447A (en) * 2014-06-20 2016-02-16 美林塔治療學有限公司 Methods for treating infections
JP2017534654A (en) 2014-11-14 2017-11-24 メリンタ セラピューティクス インコーポレイテッド Methods for treating, preventing or reducing the risk of skin infections
CN105693695A (en) * 2014-11-24 2016-06-22 重庆医药工业研究院有限责任公司 Delafloxacin meglumine salt crystal form, and preparation method thereof
CN106256824B (en) * 2015-06-18 2020-10-27 重庆医药工业研究院有限责任公司 Preparation method of high-purity delafloxacin meglumine salt
CN105017223B (en) * 2015-07-08 2017-08-01 扬子江药业集团有限公司 De Lasha star meglumine crystal formations I and preparation method thereof
CN105017224A (en) * 2015-07-10 2015-11-04 扬子江药业集团有限公司 Preparation method of Deller floxacin meglumine crystal form
CN106916142A (en) * 2015-12-25 2017-07-04 江苏奥赛康药业股份有限公司 A kind of method for preparing high-purity De Lasha stars
CN111718330A (en) * 2019-03-23 2020-09-29 南京海润医药有限公司 A kind of delafloxacin impurity III and product refining method
CN111718329A (en) * 2019-03-23 2020-09-29 南京海润医药有限公司 A kind of delafloxacin impurity IV and product refining method
CN111718331A (en) * 2019-03-23 2020-09-29 南京海润医药有限公司 Impurities I and II of Delafloxacin and product refining method
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
CN116514775B (en) * 2022-01-20 2024-11-29 安徽普利药业有限公司 A new crystal form of delafloxacin meglumine salt and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006144A1 (en) * 1995-08-03 1997-02-20 The Du Pont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
EP0911327A1 (en) * 1995-09-22 1999-04-28 Wakunaga Pharmaceutical Co., Ltd. Novel pyridonecarboxylic acid derivatives or their salts and antibacterial agent comprising the same as the active ingredient
US20030008899A1 (en) * 1999-12-08 2003-01-09 Alessandra Orlandi Heterocyclic derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1207994B (en) * 1986-01-03 1989-06-01 Therapicon Srl WATER SOLUBLE SALTS OF ANTI-INFLAMMATORY AND ANALGESIC ADAPTITY COMPOUNDS, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS.
DE69527617T2 (en) 1994-04-12 2003-04-10 Arakis Ltd., Cambridge METHOD FOR THE RACEMATE CLEAVAGE OF ETODOLAC USING GLUCAMINE DERIVATIVES
EP0945134A1 (en) 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG New galenic formulations of meloxicam for oral administration
JP2005097116A (en) 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd Alkali metal salt of quinolinecarboxylic acid derivative and method of purifying quinolinecarboxylic acid derivative using the same
HUP0204271A3 (en) 2000-01-31 2003-07-28 Pfizer Prod Inc Pyrimidine carboxamides useful as inhibitors of pde4 isozymes, pharmaceutical compositions containing them and their use
JP4337283B2 (en) 2001-07-11 2009-09-30 ソニー株式会社 Optical pickup device and recording and / or reproducing device
JP4290381B2 (en) 2002-04-11 2009-07-01 学校法人 聖マリアンナ医科大学 Emulsion containing pyridonecarboxylic acid compound
JP2004168772A (en) 2002-11-06 2004-06-17 Takeda Chem Ind Ltd Receptor modulator
EP3056492B1 (en) * 2004-10-08 2021-09-22 AbbVie Inc. Meglumine salt and crystalline forms thereof of a drug (delafloxacin)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006144A1 (en) * 1995-08-03 1997-02-20 The Du Pont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
EP0911327A1 (en) * 1995-09-22 1999-04-28 Wakunaga Pharmaceutical Co., Ltd. Novel pyridonecarboxylic acid derivatives or their salts and antibacterial agent comprising the same as the active ingredient
US20030008899A1 (en) * 1999-12-08 2003-01-09 Alessandra Orlandi Heterocyclic derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY STN INTERNATIONAL; 23 August 2001 (2001-08-23), "RN: 352458-37-8", XP002377475 *

Also Published As

Publication number Publication date
DK3056492T3 (en) 2021-12-13
LT3056492T (en) 2022-01-25
EP1802607A2 (en) 2007-07-04
EP3957632A1 (en) 2022-02-23
US20100286397A1 (en) 2010-11-11
US20070043019A1 (en) 2007-02-22
WO2006042034A2 (en) 2006-04-20
US20150196547A1 (en) 2015-07-16
EP3056492B1 (en) 2021-09-22
CA2582954A1 (en) 2006-04-20
WO2006042034A8 (en) 2007-09-07
US9873681B2 (en) 2018-01-23
US8273892B2 (en) 2012-09-25
SI3056492T1 (en) 2022-03-31
US20140155380A1 (en) 2014-06-05
US8252813B2 (en) 2012-08-28
JP5294633B2 (en) 2013-09-18
US20170073329A1 (en) 2017-03-16
HUE056718T2 (en) 2022-03-28
ES2901955T3 (en) 2022-03-24
CY1125048T1 (en) 2023-06-09
US20100261703A1 (en) 2010-10-14
US9539250B2 (en) 2017-01-10
US7728143B2 (en) 2010-06-01
MX2007004111A (en) 2007-06-14
US8648093B2 (en) 2014-02-11
PT3056492T (en) 2021-12-27
US20130060040A1 (en) 2013-03-07
PL3056492T3 (en) 2022-03-21
US8969569B2 (en) 2015-03-03
EP3056492A1 (en) 2016-08-17
US20180105510A1 (en) 2018-04-19
US10329276B2 (en) 2019-06-25
JP2008515910A (en) 2008-05-15
CA2582954C (en) 2014-07-29

Similar Documents

Publication Publication Date Title
WO2006042034A3 (en) Salt and crystalline forms thereof of a drug
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
WO2007089584A3 (en) Compositions and their uses directed to huntingtin
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2007087431A3 (en) Sublingual fentanyl spray
NO20073959L (en) Quinazoline derivative, method of preparation and use thereof for inhibiting cancer cell growth
TW200637839A (en) 1-thio-d-glucitol derivatives
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2005069865A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2009017837A3 (en) Sublingual fentanyl spray
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2007025005A3 (en) Sustained release formulations of nalbuphine
IL169484A (en) Processes for modification of the crystal habit or recrystallization of mycophenolate monosodium salt, crystals prepared by said processes, pharmaceutical compositions comprising them and their use in the treatment of diseases
WO2004060310A8 (en) Human growth hormone crystals and methods for preparing them
TW200420541A (en) Crystalline forms
DE602004008959D1 (en) BENZOÄBÜÄ1,4ÜDIOXEPINDERIVATE
TW200626158A (en) Naphthaline derivatives
WO2004098594A3 (en) Dosage form containing pantoprazole as active ingredient
WO2004087700A8 (en) Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders
WO2007134085A3 (en) Isothiazolidines useful in the treatment of ocular hypertensive conditions
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2582954

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005825344

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/004111

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007535819

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005825344

Country of ref document: EP